SOHO 2022 | The emerging potential of bispecific antibodies as monotherapy & in combination for B-cell lymphoma
Michael Dickinson, MBBS, DMedSc, FRACP, FRACPA, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses the growing role of bispecific antibodies, namely glofitamab and epcoritamab, in the treatment of aggressive B-cell lymphoma. Dr Dickinson first gives an overview of the efficacy of these two agents in patients with relapsed/refractory (R/R) disease, and then goes on to highlight the important role of bispecifics in patients who relapse after CAR-T therapy or are ineligible for stem cell transplantation. To conclude, Dr Dickinson highlights other ongoing clinical trials in this space, and the importance of optimizing the mechanism of action of these agents. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
